Insider Trading Alert - DIN, AER And MNTA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 12, 2014, 103 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $33.00 to $9,071,220.00.

Highlighted Stocks Traded by Insiders:

DineEquity (DIN) - FREE Research Report

Jakubek John, who is Svp, Human Resources at DineEquity, sold 3,500 shares at $99.90 on Dec. 12, 2014. Following this transaction, the Svp, Human Resources owned 9,518 shares meaning that the stake was reduced by 26.89% with the 3,500-share transaction.

The shares most recently traded at $99.82, down $0.08, or 0.08% since the insider transaction. Historical insider transactions for DineEquity go as follows:

  • 4-Week # shares bought: 41
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 41
  • 12-Week # shares sold: 10,000
  • 24-Week # shares bought: 41
  • 24-Week # shares sold: 140,000

The average volume for DineEquity has been 214,200 shares per day over the past 30 days. DineEquity has a market cap of $1.9 billion and is part of the services sector and leisure industry. Shares are up 19.6% year-to-date as of the close of trading on Thursday.

DineEquity, Inc., together with its subsidiaries, owns, franchises, and operates full-service restaurant chains in the United States and internationally. The stock currently has a dividend yield of 3.53%. The company has a P/E ratio of 24.6. Currently, there are 5 analysts who rate DineEquity a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on DIN - FREE

TheStreet Quant Ratings rates DineEquity as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full DineEquity Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

AerCap Holdings (AER) - FREE Research Report

Helming Keith A, who is Chief Financial Officer at AerCap Holdings, sold 25,000 shares at $41.53 on Dec. 12, 2014. Following this transaction, the Chief Financial Officer owned 318,974 shares meaning that the stake was reduced by 7.27% with the 25,000-share transaction.

The shares most recently traded at $38.78, down $2.75, or 7.09% since the insider transaction. Historical insider transactions for AerCap Holdings go as follows:

  • 4-Week # shares sold: 25,000
  • 12-Week # shares sold: 104,446
  • 24-Week # shares sold: 208,894

The average volume for AerCap Holdings has been 1.4 million shares per day over the past 30 days. AerCap Holdings has a market cap of $8.8 billion and is part of the services sector and transportation industry. Shares are up 7.3% year-to-date as of the close of trading on Thursday.

AerCap Holdings N.V., through its subsidiaries, is engaged in leasing, financing, selling, and managing commercial aircraft and engines primarily in the United States and Russia. The company has a P/E ratio of 11.0. Currently, there are 5 analysts who rate AerCap Holdings a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AER - FREE

TheStreet Quant Ratings rates AerCap Holdings as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and disappointing return on equity. Get the full AerCap Holdings Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Momenta Pharmaceuticals (MNTA) - FREE Research Report

Franken Michael, who is President, Biosimilars Busines at Momenta Pharmaceuticals, sold 2,047 shares at $12.29 on Dec. 12, 2014. Following this transaction, the President, Biosimilars Busines owned 22,953 shares meaning that the stake was reduced by 8.19% with the 2,047-share transaction.

The shares most recently traded at $12.16, down $0.13, or 1.07% since the insider transaction. Historical insider transactions for Momenta Pharmaceuticals go as follows:

  • 4-Week # shares sold: 21,170
  • 12-Week # shares sold: 24,893
  • 24-Week # shares sold: 45,343

The average volume for Momenta Pharmaceuticals has been 520,900 shares per day over the past 30 days. Momenta Pharmaceuticals has a market cap of $649.3 million and is part of the health care sector and drugs industry. Shares are down 31% year-to-date as of the close of trading on Thursday.

Momenta Pharmaceuticals, Inc., a biotechnology company, is engaged in the structural characterization, process engineering, and biologic systems analysis of complex molecules in the areas of complex generics, biosimilars, and novel drugs. Currently, there are 3 analysts who rate Momenta Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNTA - FREE

TheStreet Quant Ratings rates Momenta Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Momenta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists